Patients were younger in the ALL group, median age of 19 vs. 38 years in the AML group (P=0.001), median time from diagnosis to transplant was considerably longer in ALL patients, 15 vs. 8 months in AML patients (P=0.001); also, median CD34+ cell dose infused was higher for ALL recipients, 10x106/kg of body weight vs. 8.8x106/kg in AML cases (P=0.024). The gene discussed is CD34; the disease is acute lymphoblastic leukemia.